Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus vaccine - Seqirus

Drug Profile

Influenza virus vaccine - Seqirus

Alternative Names: Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc); FLUCELVAX; Flucelvax; Flucelvax Pediatric; FLUCELVAX QUAD; FLUCELVAX QUADRIVALENT; Flucelvax TETRA; Influenza vaccine (Flucelvax); Influenza vaccine (prepared in cell culture) - Seqirus; Optaflu; QIVc; TIVc

Latest Information Update: 14 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Seqirus
  • Class Influenza virus vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 13 Feb 2024 Seqirus completes a phase III trial in Influenza virus infections (In children, In infants, Prevention) in Lativa, Bulgaria, Poland, Czech Republic, Estonia, Bangladesh, Honduras, Malaysia, New Zealand, Philippines, Romania, Thailand, Pakistan, South Africa, Ukraine (IM) (NCT03932682) (EudraCT2018-001857-29)
  • 15 Oct 2021 Launched for Influenza virus infections (In children, In infants, Prevention) in USA (IM)
  • 15 Oct 2021 Registered for Influenza virus infections (In children, In infants, Prevention) in USA (IM)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top